Get the Stockscreener App
35.90
1.50%
0.53
After Hours:
35.90
Ionis Pharmaceuticals Inc stock is traded at $35.90, with a volume of 946.99K.
It is up +1.50% in the last 24 hours and down -8.39% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
See More
Previous Close:
$35.37
Open:
$35.4
24h Volume:
946.99K
Relative Volume:
0.57
Market Cap:
$5.28B
Revenue:
$813.46M
Net Income/Loss:
$-365.74M
P/E Ratio:
-12.51
EPS:
-2.87
Net Cash Flow:
$-375.18M
1W Performance:
+1.41%
1M Performance:
-8.39%
6M Performance:
-3.70%
1Y Performance:
-27.77%
1-Day Range:
$35.00
$36.41
1-Week Range:
$33.63
$36.41
52-Week Range:
$33.33
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
35.90 | 5.28B | 813.46M | -365.74M | -375.18M | -2.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Asia Deal Watch: Otsuka Lands Second Alliance With Ionis, Focused On ALS Subpopulation - Scrip
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Great Point Partners LLC Cuts Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Atherosclerotic Cardiovascular Disease Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amgen, Novo Nordisk, Ionis Pharma, Novartis,NewAmsterdam Pharma, ResverlogixCorp - The Globe and Mail
Hereditary Angioedema Market Expected to Experience Major - openPR
Otsuka gains global licensing rights from Ionis to ulefnersen - The Pharma Letter
Landscape Capital Management L.L.C. Makes New $1.02 Million Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Isis Pharmaceuticals, Inc. Reports Positive Phase 1 Data on Isis-ANGPTL3Rx - Marketscreener.com
Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Beta-thalassemia Market is Predicted to Exhibit Remarkable Growth During the Forecast Period, asserts DelveInsight | Phoenicia, EdiGene, Imara, Agios, Ionis - Barchart
Beta-thalassemia Market is Predicted to Exhibit Remarkable - openPR
Transthyretin Amyloidosis Treatment Market Top PlayersIonis - openPR
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angel - GuruFocus.com
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Ionis reaches agreement on phase 3 trial design for Angelman candidate - MSN
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now - MSN
Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics - Barchart
Familial Chylomicronemia Syndrome Market Expected - openPR
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks - Yahoo Finance
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Large Increase in Short Interest - MarketBeat
RSI Alert: Ionis Pharmaceuticals (IONS) Now Oversold - Nasdaq
BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals - GuruFocus.com
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year Low on Insider Selling - MarketBeat
Insider Sale: Director Joseph Loscalzo Sells Shares of Ionis Pha - GuruFocus.com
Ionis Pharmaceuticals EVP Eric Swayze sells shares worth $45,277 - Investing.com
Ionis Pharmaceuticals director Joseph Loscalzo sells shares for $511,426 - Investing.com
Ionis Pharmaceuticals CEO Brett Monia sells $252,294 in stock - Investing.com
T. Rowe Price Investment Management, Inc. Expands Stake in Ionis Pharmaceuticals Inc - GuruFocus.com
Piper Sandler Issues Pessimistic Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer - cnhinews.com
Baillie Gifford & Co. Sells 220,673 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year - Investing.com
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
StockNews.com Downgrades Ionis Pharmaceuticals (NASDAQ:IONS) to Sell - MarketBeat
What is Leerink Partnrs' Forecast for IONS FY2024 Earnings? - MarketBeat
Wellington Management Group LLP Increases Stake in Ionis Pharmac - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Call Transcript - Insider Monkey
FY2028 EPS Estimates for IONS Reduced by Leerink Partnrs - MarketBeat
ARK Investment Management LLC Buys 23,244 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus - MSN
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Ionis to present at upcoming investor conferences - GuruFocus.com
FDA agrees to review Ionis’ donidalorsen as treatment for HAE - Angioedema News Today
Is there a 2024 Duloxetine recall? FDA flags 7,100+ bottles of generic Cymbalta antidepressants - AOL
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Why Walgreens, CVS and Rite Aid are closing thousands of drug stores across America - AOL
Needham & Company LLC Reaffirms Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - MarketBeat
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - AOL
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer |
Nov 12 '24 |
Sale |
38.05 |
6,630 |
252,294 |
167,393 |
| LOSCALZO JOSEPH | Director |
Nov 12 '24 |
Sale |
37.86 |
13,508 |
511,426 |
32,251 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):